ClinicalTrials.Veeva

Menu

The Research for New Clinical Diagnostic Strategy of Specific Biomarkers for Traumatic Brain Injury

B

Baiyun Liu

Status

Enrolling

Conditions

Traumatic Brain Injury

Treatments

Diagnostic Test: diagnostic of specific biomarkers

Study type

Observational

Funder types

Other

Identifiers

NCT03976492
BTHospital KY2019-012-04

Details and patient eligibility

About

Traumatic brain injury (TBI) is the most common type of nerve injury and it severely endangers the public health. It is necessary to accurately measure the early neurological function of brain injury for monitoring its prognosis and therapeutic interventions. Glasgow Coma Score (GCS) and Computed Tomography (CT) are often used to diagnose the severity of TBI. However, GCS has its drawbacks in the observation of prognosis, because it is interfered by analgesics, sedatives and relaxants in the evaluation of neurological function. CT may miss the diagnosis of diffuse axonal injury (DAI) and the monitoring of intracranial pressure (ICP). Secondary injuries after TBI, such as oxidative stress, inflammatory damage, and abnormal metabolism, can destroy cerebral blood vessels and structures, which also affect the diagnosis of injury. Therefore, there is an urgent need for new methods to quickly identify which patients are likely to suffer brain injury or even cause persistent disability. Detection of brain injury biomarkers based on blood and brain tissue has long been used to assess the severity of TBI, but no biomarkers have been found for early diagnosis of mTBI and prognosis of different degrees of brain injury. Protein and metabolic product differences were detected from blood or the lesion samples of normal population, patients with traumatic brain injury and/or non-brain injury using mass spectrometry proteomics and metabolomics analysis platform, and diagnostic markers of potential traumatic brain injury were found, and their differential and diagnostic values were discussed.

Enrollment

450 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  1. Male and Female, aged from 18 to 65.
  2. Patients with brain injury within 24 hours after injury
  3. Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
  4. The subject reads and fully understands the instructions of the patients and signs the informed consent.

Exclusion criteria

  1. Male or female, aged below 18.
  2. Patients with definite history of central nervous system or cardiovascular system or taking drugs affecting the central nervous system.
  3. Patients with severe metabolic diseases.
  4. Pregnancy.

Trial design

450 participants in 3 patient groups

Normal group
Description:
normal population
Brain injury group
Description:
patients with traumatic brain injury within 24 hours
Treatment:
Diagnostic Test: diagnostic of specific biomarkers
Non-brain injury group
Description:
Non-brain injury group refers to patients with limb injury or systemic injury except brain injury.
Treatment:
Diagnostic Test: diagnostic of specific biomarkers

Trial contacts and locations

1

Loading...

Central trial contact

Fei Niu

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems